Get the Stockscreener App
20.48
1.04%
0.21
After Hours:
20.48
Arrowhead Pharmaceuticals Inc stock is traded at $20.48, with a volume of 1.24M.
It is up +1.04% in the last 24 hours and up +5.03% over the past month.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
See More
Previous Close:
$20.27
Open:
$20.32
24h Volume:
1.24M
Relative Volume:
0.69
Market Cap:
$2.54B
Revenue:
$181.74M
Net Income/Loss:
$-599.49M
P/E Ratio:
-4.0878
EPS:
-5.01
Net Cash Flow:
$-604.32M
1W Performance:
+1.24%
1M Performance:
+5.03%
6M Performance:
-20.80%
1Y Performance:
-38.31%
1-Day Range:
$19.95
$20.53
1-Week Range:
$18.55
$20.53
52-Week Range:
$17.05
$36.72
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Name
Arrowhead Pharmaceuticals Inc
Sector
Industry
Phone
626-696-4702
Address
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
20.48 | 2.54B | 181.74M | -599.49M | -604.32M | -5.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-24 | Initiated | Goldman | Neutral |
| Dec-04-23 | Initiated | BofA Securities | Buy |
| Sep-19-23 | Initiated | Citigroup | Neutral |
| Jul-21-23 | Initiated | TD Cowen | Outperform |
| May-12-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-12-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-11-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-19-22 | Resumed | Goldman | Buy |
| Aug-06-21 | Reiterated | Chardan Capital Markets | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-19-20 | Initiated | Citigroup | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-08-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-15-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-24-20 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Mar-17-20 | Initiated | Goldman | Neutral |
| Jan-21-20 | Initiated | SVB Leerink | Underperform |
| Dec-13-19 | Initiated | Oppenheimer | Perform |
| Nov-29-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-27-19 | Reiterated | B. Riley FBR | Buy |
| Nov-25-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-24-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-22-19 | Reiterated | Chardan Capital Markets | Buy |
| Oct-03-19 | Initiated | Robert W. Baird | Outperform |
| Sep-07-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Sep-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Aug-08-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-02-18 | Reiterated | Chardan Capital Markets | Buy |
View All
Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 5.9%Time to Sell? - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
STATE STREET CORP Reduces Stake in Arrowhead Pharmaceuticals Inc - GuruFocus.com
Objective long/short (ARWR) Report - Stock Traders Daily
Genelux Brings in Arrowhead Pharmaceuticals Exec as New Finance Chief - MarketWatch
Arrowhead Pharmaceuticals (ARWR) Expected to Announce Earnings on Monday - MarketBeat
Arrowhead Pharma Stock Soars Pre-Market On $825M Sarepta Licensing Deal: Retail Activity Hits Year-High - MSN
Arrowhead Pharmaceuticals director sells shares valued at $20,139 By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals director sells shares valued at $20,139 - MSN
Insider Selling: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Sells 959 Shares of Stock - MarketBeat
HC Wainwright Has Bearish Outlook for ARWR FY2026 Earnings - MarketBeat
What is HC Wainwright’s Estimate for ARWR FY2026 Earnings? - Defense World
RNA Editing Market Top Companies StudyQIAGEN N.V., UniquQuire - openPR
Arrowhead Pharmaceuticals' SWOT analysis: stock poised for potential breakthrough - MSN
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 4.4%Time to Sell? - MarketBeat
Leerink Partnrs Has Negative Estimate for ARWR Q3 Earnings - Defense World
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Assenagon Asset Management S.A. - Defense World
Assenagon Asset Management S.A. Reduces Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Up 6%Here's Why - MarketBeat
Leerink Partnrs Issues Negative Estimate for ARWR Earnings - MarketBeat
(ARWR) Technical Data - Stock Traders Daily
HC Wainwright Reiterates "Buy" Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat
Cantor Fitzgerald Forecasts ARWR FY2025 Earnings - Defense World
Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600 - Longview News-Journal
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results - The Bakersfield Californian
Equities Analysts Set Expectations for ARWR FY2025 Earnings - MarketBeat
FDA accepts Arrowhead's NDA for plozasiran - MSN
FDA Accepts Arrowhead Pharmaceuticals' Drug Application for Genetic Disease Treatment - MarketWatch
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Business Wire
(ARWR) Long Term Investment Analysis - Stock Traders Daily
Contrasting Janone (NASDAQ:ALTS) & Arrowhead Pharmaceuticals (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals director sells shares totaling $121,555 ate«Кавказ Пост» - «Кавказ Пост» - новости Северного Кавказа и Закавказья
Brokerages Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) PT at $43.33 - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight - GlobeNewswire Inc.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Up 3.2%Should You Buy? - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) COO Sells $578,426.88 in Stock - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Insider James C. Hamilton Sells 32,729 Shares - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CFO Kenneth Allen Myszkowski Sells 27,167 Shares - MarketBeat
Arrowhead Pharmaceuticals COO sells shares worth $736,058 By Investing.com - Investing.com Australia
Arrowhead Pharmaceuticals' chief sells $648,824 in stock By Investing.com - Investing.com Australia
Arrowhead Pharmaceuticals' chief sells $648,824 in stock - Investing.com
Arrowhead Pharmaceuticals COO sells shares worth $736,058 - Investing.com
Arrowhead Pharmaceuticals CFO Kenneth Myszkowski sells $893,095 in stock By Investing.com - Investing.com UK
Arrowhead Pharmaceuticals CEO sells $219,456 in stock By Investing.com - Investing.com Australia
Arrowhead Pharmaceuticals CEO sells $219,456 in stock - Investing.com India
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Sells $219,456.00 in Stock - MarketBeat
Arrowhead Pharmaceuticals Inc Stock (ARWR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):